The industry has recorded robust expansion, driven by rising viral conjunctivitis prevalence and accelerated drug pipeline activity. Recent approvals and strategic alliances have reshaped competitive dynamics, with industry size surpassing historical forecasts and setting the stage for sustained growth. https://www.zupyak.com/p/4605765/t/viral-conjunctivitis-drugs-market-growth-outlook-2032